Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial
Abstract
Patients with moderately active ulcerative colitis treated with 4.8 g/day of mesalamine (800 mg tablet) are significantly more likely to achieve overall improvement at 6 wk compared to patients treated with 2.4 g/day.
Keywords
Administration
National Center for Biotechnology Information
NCBI
NLM
MEDLINE
humans
pubmed abstract
nih
national institutes of health
national library of medicine
safety
treatment outcome
research support
non-u.s. gov't
adult
female
male
adolescent
aged
middle aged
Recurrence
Remission Induction
Comparative Study
Randomized Controlled Trial
Double-Blind Method
Multicenter Study
follow-up studies
placebos
Colitis
Ulcerative / drug therapy*
oral
anti-inflammatory agents
non-steroidal / adverse effects
william j sandborn
delayed-action preparations
pmid:16279903
doi:10.1111/j.1572-0241.2005.00248.x
stephen b hanauer
funmilay ajayi
non-steroidal / administration & dosage*
non-steroidal / blood
ulcerative / classification
mesalamine / administration & dosage*
mesalamine / adverse effects
mesalamine / blood
Access
Citation
ID:
270323
References
Blockchain Verification
Account:
NFT Contract Address:
0x95644003c57E6F55A65596E3D9Eac6813e3566dA
Article ID:
270323
Unique Identifier:
Network:
Scimatic Chain (ID: 481)
Loading...
Blockchain Readiness Checklist
Authors
Abstract
Journal Name
Year
Title
Creates 1,000,000 NFT tokens for this article
Token Features:
- ERC-1155 Standard NFT
- 1 Million Supply per Article
- Transferable via MetaMask
- Permanent Blockchain Record
Scan with Saymatik Web3.0 Wallet
